Literature DB >> 26220132

Pediatric cancer genomics, a play rather than a portrait.

Vijay Ramaswamy1, Michael D Taylor2.   

Abstract

Relapsed neuroblastoma is common, frequently lethal and poorly studied and poses a major treatment challenge. Two new studies shed light on the genomic landscape of recurrent neuroblastoma and demonstrate profound differences between the disease at diagnosis and relapse.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26220132     DOI： 10.1038/ng.3366

Source DB:  PubMed          Journal:  Nat Genet        ISSN： 1061-4036            Impact factor:   38.330


  7 in total

1.  EU law mandates drug testing in children.

Authors:  Gunjan Sinha
Journal:  J Natl Cancer Inst       Date:  2008-01-08       Impact factor: 13.506

Review 2.  The implications of clonal genome evolution for cancer medicine.

Authors:  Samuel Aparicio; Carlos Caldas
Journal:  N Engl J Med       Date:  2013-02-28       Impact factor: 91.245

3.  Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.

Authors:  Thomas F Eleveld; Derek A Oldridge; Virginie Bernard; Jan Koster; Léo Colmet Daage; Sharon J Diskin; Linda Schild; Nadia Bessoltane Bentahar; Angela Bellini; Mathieu Chicard; Eve Lapouble; Valérie Combaret; Patricia Legoix-Né; Jean Michon; Trevor J Pugh; Lori S Hart; JulieAnn Rader; Edward F Attiyeh; Jun S Wei; Shile Zhang; Arlene Naranjo; Julie M Gastier-Foster; Michael D Hogarty; Shahab Asgharzadeh; Malcolm A Smith; Jaime M Guidry Auvil; Thomas B K Watkins; Danny A Zwijnenburg; Marli E Ebus; Peter van Sluis; Anne Hakkert; Esther van Wezel; C Ellen van der Schoot; Ellen M Westerhout; Johannes H Schulte; Godelieve A Tytgat; M Emmy M Dolman; Isabelle Janoueix-Lerosey; Daniela S Gerhard; Huib N Caron; Olivier Delattre; Javed Khan; Rogier Versteeg; Gudrun Schleiermacher; Jan J Molenaar; John M Maris
Journal:  Nat Genet       Date:  2015-06-29       Impact factor: 38.330

4.  Mutational dynamics between primary and relapse neuroblastomas.

Authors:  Alexander Schramm; Johannes Köster; Yassen Assenov; Kristina Althoff; Martin Peifer; Ellen Mahlow; Andrea Odersky; Daniela Beisser; Corinna Ernst; Anton G Henssen; Harald Stephan; Christopher Schröder; Lukas Heukamp; Anne Engesser; Yvonne Kahlert; Jessica Theissen; Barbara Hero; Frederik Roels; Janine Altmüller; Peter Nürnberg; Kathy Astrahantseff; Christian Gloeckner; Katleen De Preter; Christoph Plass; Sangkyun Lee; Holger N Lode; Kai-Oliver Henrich; Moritz Gartlgruber; Frank Speleman; Peter Schmezer; Frank Westermann; Sven Rahmann; Matthias Fischer; Angelika Eggert; Johannes H Schulte
Journal:  Nat Genet       Date:  2015-06-29       Impact factor: 38.330

5.  Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

Authors:  Yael P Mossé; Megan S Lim; Stephan D Voss; Keith Wilner; Katherine Ruffner; Julie Laliberte; Delphine Rolland; Frank M Balis; John M Maris; Brenda J Weigel; Ashish M Ingle; Charlotte Ahern; Peter C Adamson; Susan M Blaney
Journal:  Lancet Oncol       Date:  2013-04-16       Impact factor: 41.316

6.  Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.

Authors:  Marco Gerlinger; Stuart Horswell; James Larkin; Andrew J Rowan; Max P Salm; Ignacio Varela; Rosalie Fisher; Nicholas McGranahan; Nicholas Matthews; Claudio R Santos; Pierre Martinez; Benjamin Phillimore; Sharmin Begum; Adam Rabinowitz; Bradley Spencer-Dene; Sakshi Gulati; Paul A Bates; Gordon Stamp; Lisa Pickering; Martin Gore; David L Nicol; Steven Hazell; P Andrew Futreal; Aengus Stewart; Charles Swanton
Journal:  Nat Genet       Date:  2014-02-02       Impact factor: 38.330

7.  The genetic landscape of high-risk neuroblastoma.

Authors:  Trevor J Pugh; Olena Morozova; Edward F Attiyeh; Shahab Asgharzadeh; Jun S Wei; Daniel Auclair; Scott L Carter; Kristian Cibulskis; Megan Hanna; Adam Kiezun; Jaegil Kim; Michael S Lawrence; Lee Lichenstein; Aaron McKenna; Chandra Sekhar Pedamallu; Alex H Ramos; Erica Shefler; Andrey Sivachenko; Carrie Sougnez; Chip Stewart; Adrian Ally; Inanc Birol; Readman Chiu; Richard D Corbett; Martin Hirst; Shaun D Jackman; Baljit Kamoh; Alireza Hadj Khodabakshi; Martin Krzywinski; Allan Lo; Richard A Moore; Karen L Mungall; Jenny Qian; Angela Tam; Nina Thiessen; Yongjun Zhao; Kristina A Cole; Maura Diamond; Sharon J Diskin; Yael P Mosse; Andrew C Wood; Lingyun Ji; Richard Sposto; Thomas Badgett; Wendy B London; Yvonne Moyer; Julie M Gastier-Foster; Malcolm A Smith; Jaime M Guidry Auvil; Daniela S Gerhard; Michael D Hogarty; Steven J M Jones; Eric S Lander; Stacey B Gabriel; Gad Getz; Robert C Seeger; Javed Khan; Marco A Marra; Matthew Meyerson; John M Maris
Journal:  Nat Genet       Date:  2013-01-20       Impact factor: 38.330
  7 in total
  2 in total

Review 1.  Neuroblastoma treatment in the post-genomic era.

Authors:  Maria Rosaria Esposito; Sanja Aveic; Anke Seydel; Gian Paolo Tonini
Journal:  J Biomed Sci       Date:  2017-02-08       Impact factor: 8.410

Review 2.  Precision medicine in pediatric oncology.

Authors:  Stefan E G Burdach; Mike-Andrew Westhoff; Maximilian Felix Steinhauser; Klaus-Michael Debatin
Journal:  Mol Cell Pediatr       Date:  2018-08-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.